Treatment of Fabry's disease with the pharmacologic chaperone migalastat

D. P. Germain, D. A. Hughes, K. Nicholls, D. G. Bichet, R. Giugliani, W. R. Wilcox, C. Feliciani, Suma Shankar, F. Ezgu, H. Amartino, D. Bratkovic, U. Feldt-Rasmussen, K. Nedd, U. Sharaf El Din, C. M. Lourenco, M. Banikazemi, J. Charrow, M. Dasouki, D. Finegold, P. GiraldoO. Goker-Alpan, N. Longo, C. R. Scott, R. Torra, A. Tuffaha, A. Jovanovic, S. Waldek, S. Packman, E. Ludington, C. Viereck, J. Kirk, J. Yu, E. R. Benjamin, F. Johnson, D. J. Lockhart, N. Skuban, J. Castelli, J. Barth, C. Barlow, R. Schiffmann

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

BACKGROUND: Fabry's disease, an X-linked disorder of lysosomal α-galactosidase deficiency, leads to substrate accumulation in multiple organs. Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms of α-galactosidase, increasing enzyme trafficking to lysosomes. METHODS: The initial assay of mutant α-galactosidase forms that we used to categorize 67 patients with Fabry's disease for randomization to 6 months of double-blind migalastat or placebo (stage 1), followed by open-label migalastat from 6 to 12 months (stage 2) plus an additional year, had certain limitations. Before unblinding, a new, validated assay showed that 50 of the 67 participants had mutant α-galactosidase forms suitable for targeting by migalastat. The primary end point was the percentage of patients who had a response (≥50% reduction in the number of globotriaosylceramide inclusions per kidney interstitial capillary) at 6 months. We assessed safety along with disease substrates and renal, cardiovascular, and patient-reported outcomes. RESULTS: The primary end-point analysis, involving patients with mutant α-galactosidase forms that were suitable or not suitable for migalastat therapy, did not show a significant treatment effect: 13 of 32 patients (41%) who received migalastat and 9 of 32 patients (28%) who received placebo had a response at 6 months (P=0.30). Among patients with suitable mutant α-galactosidase who received migalastat for up to 24 months, the annualized changes from baseline in the estimated glomerular filtration rate (GFR) and measured GFR were -0.30±0.66 and -1.51±1.33 ml per minute per 1.73 m2 of body-surface area, respectively. The left-ventricular-mass index decreased significantly from baseline (-7.7 g per square meter; 95% confidence interval [CI], -15.4 to -0.01), particularly when left ventricular hypertrophy was present (-18.6 g per square meter; 95% CI, -38.2 to 1.0). The severity of diarrhea, reflux, and indigestion decreased. CONCLUSIONS: Among all randomly assigned patients (with mutant α-galactosidase forms that were suitable or not suitable for migalastat therapy), the percentage of patients who had a response at 6 months did not differ significantly between the migalastat group and the placebo group.

Original languageEnglish (US)
Pages (from-to)545-555
Number of pages11
JournalNew England Journal of Medicine
Volume375
Issue number6
DOIs
StatePublished - Aug 11 2016
Externally publishedYes

Fingerprint

Fabry Disease
Galactosidases
Therapeutics
Placebos
Glomerular Filtration Rate
Confidence Intervals
Kidney
migalastat
Dyspepsia
Body Surface Area
Left Ventricular Hypertrophy
Random Allocation
Lysosomes
Diarrhea
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Germain, D. P., Hughes, D. A., Nicholls, K., Bichet, D. G., Giugliani, R., Wilcox, W. R., ... Schiffmann, R. (2016). Treatment of Fabry's disease with the pharmacologic chaperone migalastat. New England Journal of Medicine, 375(6), 545-555. https://doi.org/10.1056/NEJMoa1510198

Treatment of Fabry's disease with the pharmacologic chaperone migalastat. / Germain, D. P.; Hughes, D. A.; Nicholls, K.; Bichet, D. G.; Giugliani, R.; Wilcox, W. R.; Feliciani, C.; Shankar, Suma; Ezgu, F.; Amartino, H.; Bratkovic, D.; Feldt-Rasmussen, U.; Nedd, K.; Sharaf El Din, U.; Lourenco, C. M.; Banikazemi, M.; Charrow, J.; Dasouki, M.; Finegold, D.; Giraldo, P.; Goker-Alpan, O.; Longo, N.; Scott, C. R.; Torra, R.; Tuffaha, A.; Jovanovic, A.; Waldek, S.; Packman, S.; Ludington, E.; Viereck, C.; Kirk, J.; Yu, J.; Benjamin, E. R.; Johnson, F.; Lockhart, D. J.; Skuban, N.; Castelli, J.; Barth, J.; Barlow, C.; Schiffmann, R.

In: New England Journal of Medicine, Vol. 375, No. 6, 11.08.2016, p. 545-555.

Research output: Contribution to journalArticle

Germain, DP, Hughes, DA, Nicholls, K, Bichet, DG, Giugliani, R, Wilcox, WR, Feliciani, C, Shankar, S, Ezgu, F, Amartino, H, Bratkovic, D, Feldt-Rasmussen, U, Nedd, K, Sharaf El Din, U, Lourenco, CM, Banikazemi, M, Charrow, J, Dasouki, M, Finegold, D, Giraldo, P, Goker-Alpan, O, Longo, N, Scott, CR, Torra, R, Tuffaha, A, Jovanovic, A, Waldek, S, Packman, S, Ludington, E, Viereck, C, Kirk, J, Yu, J, Benjamin, ER, Johnson, F, Lockhart, DJ, Skuban, N, Castelli, J, Barth, J, Barlow, C & Schiffmann, R 2016, 'Treatment of Fabry's disease with the pharmacologic chaperone migalastat', New England Journal of Medicine, vol. 375, no. 6, pp. 545-555. https://doi.org/10.1056/NEJMoa1510198
Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR et al. Treatment of Fabry's disease with the pharmacologic chaperone migalastat. New England Journal of Medicine. 2016 Aug 11;375(6):545-555. https://doi.org/10.1056/NEJMoa1510198
Germain, D. P. ; Hughes, D. A. ; Nicholls, K. ; Bichet, D. G. ; Giugliani, R. ; Wilcox, W. R. ; Feliciani, C. ; Shankar, Suma ; Ezgu, F. ; Amartino, H. ; Bratkovic, D. ; Feldt-Rasmussen, U. ; Nedd, K. ; Sharaf El Din, U. ; Lourenco, C. M. ; Banikazemi, M. ; Charrow, J. ; Dasouki, M. ; Finegold, D. ; Giraldo, P. ; Goker-Alpan, O. ; Longo, N. ; Scott, C. R. ; Torra, R. ; Tuffaha, A. ; Jovanovic, A. ; Waldek, S. ; Packman, S. ; Ludington, E. ; Viereck, C. ; Kirk, J. ; Yu, J. ; Benjamin, E. R. ; Johnson, F. ; Lockhart, D. J. ; Skuban, N. ; Castelli, J. ; Barth, J. ; Barlow, C. ; Schiffmann, R. / Treatment of Fabry's disease with the pharmacologic chaperone migalastat. In: New England Journal of Medicine. 2016 ; Vol. 375, No. 6. pp. 545-555.
@article{3eabcbc96ab24e1781866fdd1a2c3d40,
title = "Treatment of Fabry's disease with the pharmacologic chaperone migalastat",
abstract = "BACKGROUND: Fabry's disease, an X-linked disorder of lysosomal α-galactosidase deficiency, leads to substrate accumulation in multiple organs. Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms of α-galactosidase, increasing enzyme trafficking to lysosomes. METHODS: The initial assay of mutant α-galactosidase forms that we used to categorize 67 patients with Fabry's disease for randomization to 6 months of double-blind migalastat or placebo (stage 1), followed by open-label migalastat from 6 to 12 months (stage 2) plus an additional year, had certain limitations. Before unblinding, a new, validated assay showed that 50 of the 67 participants had mutant α-galactosidase forms suitable for targeting by migalastat. The primary end point was the percentage of patients who had a response (≥50{\%} reduction in the number of globotriaosylceramide inclusions per kidney interstitial capillary) at 6 months. We assessed safety along with disease substrates and renal, cardiovascular, and patient-reported outcomes. RESULTS: The primary end-point analysis, involving patients with mutant α-galactosidase forms that were suitable or not suitable for migalastat therapy, did not show a significant treatment effect: 13 of 32 patients (41{\%}) who received migalastat and 9 of 32 patients (28{\%}) who received placebo had a response at 6 months (P=0.30). Among patients with suitable mutant α-galactosidase who received migalastat for up to 24 months, the annualized changes from baseline in the estimated glomerular filtration rate (GFR) and measured GFR were -0.30±0.66 and -1.51±1.33 ml per minute per 1.73 m2 of body-surface area, respectively. The left-ventricular-mass index decreased significantly from baseline (-7.7 g per square meter; 95{\%} confidence interval [CI], -15.4 to -0.01), particularly when left ventricular hypertrophy was present (-18.6 g per square meter; 95{\%} CI, -38.2 to 1.0). The severity of diarrhea, reflux, and indigestion decreased. CONCLUSIONS: Among all randomly assigned patients (with mutant α-galactosidase forms that were suitable or not suitable for migalastat therapy), the percentage of patients who had a response at 6 months did not differ significantly between the migalastat group and the placebo group.",
author = "Germain, {D. P.} and Hughes, {D. A.} and K. Nicholls and Bichet, {D. G.} and R. Giugliani and Wilcox, {W. R.} and C. Feliciani and Suma Shankar and F. Ezgu and H. Amartino and D. Bratkovic and U. Feldt-Rasmussen and K. Nedd and {Sharaf El Din}, U. and Lourenco, {C. M.} and M. Banikazemi and J. Charrow and M. Dasouki and D. Finegold and P. Giraldo and O. Goker-Alpan and N. Longo and Scott, {C. R.} and R. Torra and A. Tuffaha and A. Jovanovic and S. Waldek and S. Packman and E. Ludington and C. Viereck and J. Kirk and J. Yu and Benjamin, {E. R.} and F. Johnson and Lockhart, {D. J.} and N. Skuban and J. Castelli and J. Barth and C. Barlow and R. Schiffmann",
year = "2016",
month = "8",
day = "11",
doi = "10.1056/NEJMoa1510198",
language = "English (US)",
volume = "375",
pages = "545--555",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "6",

}

TY - JOUR

T1 - Treatment of Fabry's disease with the pharmacologic chaperone migalastat

AU - Germain, D. P.

AU - Hughes, D. A.

AU - Nicholls, K.

AU - Bichet, D. G.

AU - Giugliani, R.

AU - Wilcox, W. R.

AU - Feliciani, C.

AU - Shankar, Suma

AU - Ezgu, F.

AU - Amartino, H.

AU - Bratkovic, D.

AU - Feldt-Rasmussen, U.

AU - Nedd, K.

AU - Sharaf El Din, U.

AU - Lourenco, C. M.

AU - Banikazemi, M.

AU - Charrow, J.

AU - Dasouki, M.

AU - Finegold, D.

AU - Giraldo, P.

AU - Goker-Alpan, O.

AU - Longo, N.

AU - Scott, C. R.

AU - Torra, R.

AU - Tuffaha, A.

AU - Jovanovic, A.

AU - Waldek, S.

AU - Packman, S.

AU - Ludington, E.

AU - Viereck, C.

AU - Kirk, J.

AU - Yu, J.

AU - Benjamin, E. R.

AU - Johnson, F.

AU - Lockhart, D. J.

AU - Skuban, N.

AU - Castelli, J.

AU - Barth, J.

AU - Barlow, C.

AU - Schiffmann, R.

PY - 2016/8/11

Y1 - 2016/8/11

N2 - BACKGROUND: Fabry's disease, an X-linked disorder of lysosomal α-galactosidase deficiency, leads to substrate accumulation in multiple organs. Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms of α-galactosidase, increasing enzyme trafficking to lysosomes. METHODS: The initial assay of mutant α-galactosidase forms that we used to categorize 67 patients with Fabry's disease for randomization to 6 months of double-blind migalastat or placebo (stage 1), followed by open-label migalastat from 6 to 12 months (stage 2) plus an additional year, had certain limitations. Before unblinding, a new, validated assay showed that 50 of the 67 participants had mutant α-galactosidase forms suitable for targeting by migalastat. The primary end point was the percentage of patients who had a response (≥50% reduction in the number of globotriaosylceramide inclusions per kidney interstitial capillary) at 6 months. We assessed safety along with disease substrates and renal, cardiovascular, and patient-reported outcomes. RESULTS: The primary end-point analysis, involving patients with mutant α-galactosidase forms that were suitable or not suitable for migalastat therapy, did not show a significant treatment effect: 13 of 32 patients (41%) who received migalastat and 9 of 32 patients (28%) who received placebo had a response at 6 months (P=0.30). Among patients with suitable mutant α-galactosidase who received migalastat for up to 24 months, the annualized changes from baseline in the estimated glomerular filtration rate (GFR) and measured GFR were -0.30±0.66 and -1.51±1.33 ml per minute per 1.73 m2 of body-surface area, respectively. The left-ventricular-mass index decreased significantly from baseline (-7.7 g per square meter; 95% confidence interval [CI], -15.4 to -0.01), particularly when left ventricular hypertrophy was present (-18.6 g per square meter; 95% CI, -38.2 to 1.0). The severity of diarrhea, reflux, and indigestion decreased. CONCLUSIONS: Among all randomly assigned patients (with mutant α-galactosidase forms that were suitable or not suitable for migalastat therapy), the percentage of patients who had a response at 6 months did not differ significantly between the migalastat group and the placebo group.

AB - BACKGROUND: Fabry's disease, an X-linked disorder of lysosomal α-galactosidase deficiency, leads to substrate accumulation in multiple organs. Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms of α-galactosidase, increasing enzyme trafficking to lysosomes. METHODS: The initial assay of mutant α-galactosidase forms that we used to categorize 67 patients with Fabry's disease for randomization to 6 months of double-blind migalastat or placebo (stage 1), followed by open-label migalastat from 6 to 12 months (stage 2) plus an additional year, had certain limitations. Before unblinding, a new, validated assay showed that 50 of the 67 participants had mutant α-galactosidase forms suitable for targeting by migalastat. The primary end point was the percentage of patients who had a response (≥50% reduction in the number of globotriaosylceramide inclusions per kidney interstitial capillary) at 6 months. We assessed safety along with disease substrates and renal, cardiovascular, and patient-reported outcomes. RESULTS: The primary end-point analysis, involving patients with mutant α-galactosidase forms that were suitable or not suitable for migalastat therapy, did not show a significant treatment effect: 13 of 32 patients (41%) who received migalastat and 9 of 32 patients (28%) who received placebo had a response at 6 months (P=0.30). Among patients with suitable mutant α-galactosidase who received migalastat for up to 24 months, the annualized changes from baseline in the estimated glomerular filtration rate (GFR) and measured GFR were -0.30±0.66 and -1.51±1.33 ml per minute per 1.73 m2 of body-surface area, respectively. The left-ventricular-mass index decreased significantly from baseline (-7.7 g per square meter; 95% confidence interval [CI], -15.4 to -0.01), particularly when left ventricular hypertrophy was present (-18.6 g per square meter; 95% CI, -38.2 to 1.0). The severity of diarrhea, reflux, and indigestion decreased. CONCLUSIONS: Among all randomly assigned patients (with mutant α-galactosidase forms that were suitable or not suitable for migalastat therapy), the percentage of patients who had a response at 6 months did not differ significantly between the migalastat group and the placebo group.

UR - http://www.scopus.com/inward/record.url?scp=84981742779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981742779&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1510198

DO - 10.1056/NEJMoa1510198

M3 - Article

C2 - 27509102

AN - SCOPUS:84981742779

VL - 375

SP - 545

EP - 555

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 6

ER -